At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 36 enrolled
Drug / intervention
Melatonin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anxiolytic and Analgesic Effects of Melatonin: A Randomized, Double-blinded, Placebo-controlled Clinical Study
In Brief
A Phase 3 clinical trial evaluating Melatonin and Placebo for Anxiety. Completed, enrolled 36 participants across 1 site.
Detailed Summary
The study's main objective is to investigate melatonin's anxiolytic and sleep-regulating effects in patients undergoing surgery. Moreover, the investigators intend to investigate the pharmacokinetic parameters of melatonin in this patient population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnxiety
CountriesDenmark
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartAug 2016
Primary CompletionMar 2021
Study CompletionApr 2021
TodayJul 2026
First PostedMar 11, 2015
Enrollment StartAug 1, 2016
Primary CompletionMar 1, 2021
Study CompletionApr 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 11.3 years ago
Interventions
Melatonindrug
Gelatin capsules
Placebodrug
Placebo capsules